Whole blood RNA expression profiles in ovarian cancer patients with or without residual tumors after primary cytoreductive surgery

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1331-1335

  Isaksson, Helena S ^a,b   Sorbe, Bengt ^a   Nilsson, Torbjörn K ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Leukocyte gene expression; Residual tumor; Seropapillary ovarian cancer; Whole blood RNA expression

Indexed keywords

ALPHA CATENIN; BINDING PROTEIN; INTERLEUKIN 1BETA; METASTASIS ASSOCIATED 1 FAMILY MEMBER 2 PROTEIN; METASTIN; RNA; STROMELYSIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; LEUKOCYTE; METASTASIS; MINIMAL RESIDUAL DISEASE; OVARY CANCER; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84858269622     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1680     Document Type: Article

References (23)

1. Pellicciotta I, Yang CPH, Goldberg GL and Shahabi S: Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells. Gynecol Oncol 122: 625-631, 2011.
2. Mury D, Woelber L, Jung S, et al: Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol 137: 1131-1137, 2011.
3. Eskander RN and Randall LM: Bevacizumab in the treatment of ovarian cancer. Biologics 5: 1-5, 2011.
4. Gardner GJ and Jewell EL: Current and future directions of clinical trials for ovarian cancer. Cancer Control 18: 44-51, 2011.
5. Skírnisdóttir I and Sorbe B: Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer 18: 345-351, 2008. (Pubitemid 351365212)
6. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59, 2009.
7. Poveda A, Kaye SB, McCormack R, et al: Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 122: 567-572, 2011.
8. Rotunno M, Hu N, Su H, et al: A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. Cancer Prev Res (Phila) 4: 1599-1608, 2011.
9. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
10. Pokutta S, Drees F, Yamada S, Nelson WJ and Weis WI: Biochemical and structural analysis of alpha-catenin in cell-cell contacts. Biochem Soc Trans 36: 141-147, 2008. (Pubitemid 351570583)
11. Shibata H, Takano H, Ito M, et al: Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci USA 104: 18199-18204, 2007. (Pubitemid 350210844)
12. Davidson B, Berner A, Nesland JM, et al: E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 192: 460-469, 2000.
13. Jiang Y, Berk M, Singh LS, et al: KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin Exp Metastasis 22: 369-376, 2005. (Pubitemid 41609296)
14. Navenot JM, Fujii N and Peiper SC: KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Mol Pharmacol 75: 1074-1083, 2009.
15. Toh Y and Nicolson GL: The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 26: 215-227, 2009.
16. Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999. (Pubitemid 129519680)
17. Miyata Y, Iwata T, Maruta S, et al: Expression of matrix metalloproteinase- 10 in renal cell carcinoma and its prognostic role. Eur Urol 52: 791-797, 2007. (Pubitemid 47126131)
18. Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A and Zienolddiny S: A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis 30: 1186-1192, 2009.
19. Lee JY, Jung HJ, Song IS, et al: Protective role of cytosolic 2-cys peroxiredoxin in the TNF-[alpha]-induced apoptotic death of human cancer cells. Free Radic Biol Med 47: 1162-1171, 2009.
20. Galamb O, Sipos F, Solymosi N, et al: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev 17: 2835-2845, 2008.
21. Atz M, Walsh D, Cartagena P, et al: Methodological considerations for gene expression profiling of human brain. J Neurosci Methods 163: 295-309, 2007. (Pubitemid 46874608)
22. Armugam A, Cher CD, Lim K, Koh DC, Howells DW and Jeyaseelan K: A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis. BMC Neurosci 10: 120, 2009.
23. Block T, Isaksson HS, Acosta S, Bjorck M, Brodin D and Nilsson TK: Altered mRNA expression due to acute mesenteric ischaemia in a porcine model. Eur J Vasc Endovasc Surg 41: 281-287, 2011.